

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/215768 A3

(51) International Patent Classification:

C12P 21/08 (2006.01) G01N 33/53 (2006.01)
C12N 15/13 (2006.01) G01N 33/68 (2006.01)
C12N 15/63 (2006.01) C07K 16/18 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2023/066523

(22) International Filing Date:

02 May 2023 (02.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/337,980 03 May 2022 (03.05.2022) US
63/359,541 08 July 2022 (08.07.2022) US

(88) Date of publication of the international search report:

11 January 2024 (11.01.2024)

(71) Applicant: **MBRACE THERAPEUTICS, INC.**
[US/US]; 4660 La Jolla Village Drive, Suite 950, San
Diego, California 92121 (US).

(72) Inventors: **STAQUICINI, Fernanda, I.**; MBrace Thera-
peutics, Inc., 4660 La Jolla Village Drive, Suite 950, San
Diego, California 92121 (US). **PASQUALINI, Renata**;
MBrace Therapeutics, Inc., 4660 La Jolla Village Drive,
Suite 950, San Diego, California 92121 (US).

(74) Agent: **HALLORAN, Patrick** et al.; 80 M Street SE, 1st
Floor, Washington, District of Columbia 20003 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS OF RECOMBINANT ANTIBODY PRODUCTION AND RELATED CELL SYSTEMS

(57) Abstract: Provided herein are methods and cell systems for production of a recombinant antibody in cells in which the antibody is directed against a target protein that is natively expressed as an intracellular protein in the cell. Also provided herein are modified cell lines for use in such methods in which the modified cell line is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

WO 2023/215768 A3